Aprovask 5 mg + 150 mg: oval, biconvex, white color, on one party there is an engraving "150/5" (on 7 pieces in blisters, in a cardboard pack 2 or 4 blisters);
Aprovask 10 mg + 150 mg: oval, biconvex, pink color, on one party there is an engraving "150/10" (on 7 pieces in blisters, in a cardboard pack 2 or 4 blisters);
Aprovask 5 mg + 300 mg: oval, biconvex, yellow color, on one party there is an engraving "300/5" (on 7 pieces in blisters, in a cardboard pack 2 or 4 blisters);
Aprovask 10 mg + 300 mg: oval, biconvex, white color, on one party there is risk and a bevel to it (on 7 pieces in blisters, in a cardboard pack 2 or 4 blisters).

Structure of 1 tablet:

active ingredients: амлодипин (in the form of an amlodipin of a bezilat) – 5 mg or 10 mg, ирбесартан – 150 mg or 300 mg;
auxiliary components: gipromelloza 6 мПа.с, silicon dioxide colloid, cellulose of microcrystallic 50 microns, cellulose of microcrystallic 100 microns, magnesium stearate, croscarmellose sodium;
structure of a film cover: опадрай white (Aprovask 5 mg + 150 mg and Aprovask 10 mg + 300 mg), опадрай pink (Aprovask 10 mg + 150 mg) or опадрай yellow (Aprovask 5 mg + 300 mg).

Indications to use

Aprovask is appointed at arterial hypertension in case of inefficiency of monotherapy amlodipiny or irbesartany.

Contraindications

Absolute:

unstable stenocardia (except Printsmetal's stenocardia);
cardiogenic shock;
clinically significant stenosis of the aortal valve;
concomitant use with inhibitors of an angiotensin-converting enzyme at patients with a diabetic nephropathy;
concomitant use with drugs which part is алискирен, at persons with a diabetes mellitus or a renal failure of moderately expressed or heavy degree;
children's and teenage age up to 18 years (as safety and efficiency of drug are not established);
pregnancy period;
lactation period;
hypersensitivity to the main or auxiliary components of drug, and also other derivatives of dihydropyridine.

Relative (Aprovask is applied with care):

chronic heart failure 2-3 functional classes;
stenosis of the mitral and aortal valve or hypertrophic subaortic stenosis;
coronary heart disease and/or clinically significant atherosclerosis of vessels of a brain;
sick sinus syndrome;
renal failure and the postoperative period after transplantation of a kidney;
liver failure;
hyponatremia and hypovolemia;
states at which function of kidneys depends on activity system renin-angiotensin-aldosteronovoy (arterial hypertension with a renal artery stenosis of both kidneys or one kidney, chronic heart failure 3-4 functional classes).

Route of administration and dosage

Aprovask is accepted inside, irrespective of meal. The tablet should be swallowed entirely, washing down with water.

As a rule, the initial and supporting doses make on 1 tablet a day.

Aprovask is appointed to patients at inefficiency of monotherapy amlodipiny or irbesartany, and also that who already accepts амлодипин and ирбесартан in the form of separate tablets. The dose is selected individually, and at first drugs of an amlodipin and irbesartan are applied separately. At selection of a dose reaction of arterial pressure upon the carried-out treatment and target value of arterial pressure is considered. The maximum daily dose of drug makes 150 mg / 10 mg or 300 mg / 10 mg.

And to elderly people reduction of a dose is not required to patients with renal failures.

At abnormal liver functions Aprovask is appointed with care.

Side effects

The undesirable side effects observed during treatment by drug Aprovask:

alimentary system: often – puffiness of gums; infrequently – pains in an upper part of a stomach, nausea, a lock;
metabolism: infrequently – a hyperpotassemia;
respiratory system: infrequently – cough;
cardiovascular system: often – orthostatic hypotension, a heart consciousness; infrequently – an excessive lowering of arterial pressure, a sinus bradycardia;
nervous system: often – drowsiness, a headache, dizziness; infrequently – paresthesia;
sense bodys: infrequently – вертиго;
musculoskeletal system: infrequently – an arthralgia, rigidity of joints, a mialgiya;
urinary system: often – a proteinuria; infrequently – a hypercreatinemia, an azotemia;
reproductive system: infrequently – erectile dysfunction;
other reactions: often – hypostases, peripheral hypostases; infrequently – an asthenic state.

The undesirable side effects observed in clinical trials and post-marketing use of an irbesartan:

alimentary system: often – pains in an upper part of a stomach, a glossitis, nausea and vomiting, a food faddism; infrequently – heartburn, dyspepsia, diarrhea; frequency is unknown – hepatitis, jaundice, increase in activity of enzymes of a liver;
metabolism: frequency is unknown – a hyperpotassemia;
respiratory system: infrequently – cough;
cardiovascular system: infrequently – tachycardia;
nervous system: often – dizziness, a headache; infrequently – orthostatic dizziness;
sense bodys: often – вертиго; frequency is unknown – a sonitus;
musculoskeletal system: frequency is unknown – a mialgiya;
urinary system: frequency is unknown – a renal failure;
reproductive system: infrequently – erectile dysfunction;
skin and hypodermic fabrics: infrequently – baldness; frequency is unknown – a leykotsitoklastichesky vasculitis;
immune system: frequency is unknown – a small tortoiseshell, a Quincke's disease and other reactions of hypersensitivity;
other reactions: often – hypostases, increased fatigue; infrequently – falling, thorax pains; frequency is unknown – an asthenic state.

The undesirable side effects observed in clinical trials at use of an amlodipin:

alimentary system: often – abdominal pains, a glossitis, nausea, a glossodynia; infrequently – dyspepsia, dryness of mucous membranes of an oral cavity, change of a rhythm of defecation, vomiting; very seldom – jaundice, hepatitis, gastritis, pancreatitis, a hyperplasia of gums, increase in activity of enzymes of a liver;
metabolism: very seldom – a hyperglycemia;
respiratory system: often – cough; infrequently – rhinitis, short wind; very seldom – a tussiculation;
cardiovascular system: often – reddening of covers of skin, inflows, a heart consciousness; very seldom – disturbance of a heart rhythm, a vasculitis, a myocardial infarction, fibrillation of auricles and ventricular tachycardia;
nervous system and mentality: often – drowsiness, dizziness, a headache; infrequently – lability of mood, a food faddism, paresthesia, sleeplessness, syncopal states, a tremor, a hypesthesia; very seldom – a peripheral neuropathy;
sense bodys: infrequently – вертиго, visual frustration, a ring in ears;
musculoskeletal system: infrequently – a mialgiya, muscular spasms, dorsodynias, an arthralgia;
urinary system: infrequently – painful desires on an urination, increase in frequency of an urination, a nocturia;
reproductive system: infrequently – a gynecomastia, impotence;
skin and hypodermic fabrics: often – contact dermatitis; infrequently – baldness, an itch, the increased sweating, skin rash, a purpura, change of a xanthopathy; very seldom – a mnogoformny exudative erythema;
immune system: very seldom – a small tortoiseshell, a Quincke's disease and other allergic reactions;
hemopoietic system: very seldom – thrombocytopenia;
tool data and laboratory indicators: infrequently – decrease or increase in body weight;
other reactions: often – hypostases, increased fatigue, peripheral hypostases; infrequently – an asthenic state, pains, feeling of an indisposition, thorax pain; seldom – a face edema.

Special instructions

Drug influence Aprovask on ability of the person to manage motor transport or to be engaged in the work demanding the increased concentration of attention and bystry reaction was not studied. Considering pharmakodinamichesky properties of drug, its influence on such ability is improbable. It is not recommended to drive the car or to be engaged in potentially dangerous activity in case of such side reactions as вертиго, dizziness and weakness.